Evidence map›Paper›PMID 30866739›Full record

ArticleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2019

Discovery reliability.

Anders Hånell

Abstract read
In one paragraph

Article in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Anders HånellDepartment of Neuroscience, The Karolinska Institute, Stockholm, Sweden.ORCID 0000-0001-9369-3886

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Whenever an experiment yields a statistically significant outcome you should ask yourself: To what extent can I trust this result? This is especially important for pre-clinical drug studies because of the frequent failures of phase III clinical trials of neurological diseases, which has put the reliability of pre-clinical research into question. Two important factors, the pre-study likelihood of treatment benefit, and statistical power, affects the reliability of the result in a quantifiable way. This can be used to assess to what extent the result of a study can be trusted (discovery reliability), and to guide the design of pre-clinical research.

Indexed as

AnimalsDrug Evaluation, PreclinicalHumansModels, StatisticalResearch DesignSample SizeAnimal modelsanimal studiesbiostatisticsclinical trial designmathematical modeling

Identifiers

PMID30866739
PMCPMC6547187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.